Liberum Capital Keeps a “Buy” Rating on RPS Group PLC (LON:RPS) and GBX 310.00 Target; Last Week Retrophin, Inc. (RTRX) Coverage

Among 4 analysts covering Retrophin (NASDAQ:RTRX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Retrophin has $44 highest and $25 lowest target. $39.33’s average target is 64.49% above currents $23.91 stock price. Retrophin had 7 analyst reports since August 12, 2015 according to SRatingsIntel. The rating was initiated by JMP Securities with “Mkt Outperform” on Monday, November 2. BMO Capital Markets initiated Retrophin, Inc. (NASDAQ:RTRX) rating on Tuesday, April 12. BMO Capital Markets has “Outperform” rating and $25 target. The firm earned “Buy” rating on Tuesday, November 7 by BMO Capital Markets. Zacks downgraded the stock to “Buy” rating in Wednesday, August 12 report. The rating was maintained by BMO Capital Markets with “Buy” on Friday, October 6. See Retrophin, Inc. (NASDAQ:RTRX) latest ratings:

07/11/2017 Broker: BMO Capital Markets Rating: Buy New Target: $44.0 Maintain
06/10/2017 Broker: BMO Capital Markets Rating: Buy New Target: $44.0 Maintain

In a research note revealed to investors and clients on today, Liberum Capital restate their “Buy” rating on RPS Group PLC (LON:RPS)‘s stock. The target would suggest a potential upside of 17.20% from firm’s last close price.

RPS Group Plc, a consultancy company, provides advice on the evaluation and development of energy, water, and other resources; and development and management of the built and natural environment. The company has market cap of 588.31 million GBP. The firm operates through Built and Natural Environment, Energy, and Australia Asia Pacific divisions. It has a 19.42 P/E ratio. It offers consultancy services, including environmental assessment, project management, water resources management, due diligence, oceanography, health and safety, risk management, town and country planning, building, landscape and urban design, surveying, and transport planning to various aspects of the property and infrastructure development and management sectors.

The stock decreased 7.38% or GBX 21.5 during the last trading session, reaching GBX 270. About 824,472 shares traded or 329.90% up from the average. RPS Group plc (LON:RPS) has 0.00% since February 1, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 5 analysts covering RPS Group PLC (LON:RPS), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. RPS Group PLC has GBX 330 highest and GBX 167 lowest target. GBX 275.80’s average target is 2.15% above currents GBX 270 stock price. RPS Group PLC had 51 analyst reports since July 30, 2015 according to SRatingsIntel. The rating was maintained by Liberum Capital with “Buy” on Thursday, March 2. Liberum Capital maintained RPS Group plc (LON:RPS) rating on Wednesday, February 17. Liberum Capital has “Buy” rating and GBX 240 target. Liberum Capital maintained the stock with “Buy” rating in Tuesday, May 2 report. The company was maintained on Thursday, August 4 by Peel Hunt. The firm has “Buy” rating by Liberum Capital given on Friday, August 4. Peel Hunt maintained the shares of RPS in report on Friday, February 10 with “Hold” rating. The stock of RPS Group plc (LON:RPS) earned “Sell” rating by Panmure Gordon on Thursday, July 30. Numis Securities maintained RPS Group plc (LON:RPS) on Friday, October 30 with “Buy” rating. Liberum Capital maintained the shares of RPS in report on Tuesday, November 29 with “Buy” rating. Sanlam Securities maintained the shares of RPS in report on Thursday, August 13 with “Buy” rating.

Since August 16, 2017, it had 0 insider purchases, and 2 insider sales for $53,651 activity. Another trade for 1,378 shares valued at $31,005 was sold by McFarlane Neil F.. $22,646 worth of Retrophin, Inc. (NASDAQ:RTRX) shares were sold by REED ELIZABETH E.

Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. The company has market cap of $939.82 million. The Company’s marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. It currently has negative earnings. The companyÂ’s product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc , a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis.